Drug intelligence / Profile preview

PF-05231023

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules

Overview

PF-05231023 is a long-acting fibroblast growth factor 21 (FGF21) analog. It acts as an FGF21 receptor agonist and has been studied for its potential in treating obesity and type 2 diabetes mellitus. PF-05231023 has shown effects on weight loss, improved lipid profiles, and enhanced glucose tolerance in various studies. It is also used as a PEG-based PROTAC linker in research settings.

Other names: Mal-PEG2-AZDMal-PEG-2-AZDMal-PEG 2-AZD

Targets

FGFR1 (Fibroblast growth factor receptor 1)

Beyond the preview

Go deeper on PF-05231023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-05231023.

Explore the full profile